VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Average Recommendation of “Reduce” by Brokerages

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has been given a consensus recommendation of “Reduce” by the five analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $0.95.

Several research analysts have weighed in on VTGN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen lowered VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st.

Institutional Trading of VistaGen Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VTGN. Geode Capital Management LLC increased its stake in shares of VistaGen Therapeutics by 18.3% during the 4th quarter. Geode Capital Management LLC now owns 352,836 shares of the company’s stock worth $234,000 after purchasing an additional 54,556 shares during the last quarter. Luminus Management LLC bought a new position in shares of VistaGen Therapeutics during the 4th quarter valued at $232,000. Renaissance Technologies LLC lifted its stake in shares of VistaGen Therapeutics by 81.2% in the 1st quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock valued at $166,000 after purchasing an additional 130,509 shares during the last quarter. Two Sigma Investments LP boosted its holdings in VistaGen Therapeutics by 223.5% in the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock worth $1,027,000 after purchasing an additional 199,958 shares in the last quarter. Finally, AdvisorShares Investments LLC boosted its holdings in VistaGen Therapeutics by 10.8% in the first quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock worth $158,000 after purchasing an additional 26,922 shares in the last quarter. 78.39% of the stock is currently owned by institutional investors and hedge funds.

VistaGen Therapeutics Stock Down 4.0%

Shares of NASDAQ:VTGN traded down $0.03 during trading on Friday, reaching $0.62. 655,298 shares of the company traded hands, compared to its average volume of 1,235,241. The firm has a fifty day simple moving average of $0.60 and a 200 day simple moving average of $1.55. The firm has a market cap of $24.76 million, a P/E ratio of -0.33 and a beta of 0.31. VistaGen Therapeutics has a 1-year low of $0.43 and a 1-year high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.14 million. As a group, research analysts anticipate that VistaGen Therapeutics will post -1.88 EPS for the current year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.